Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-1: DMT310 in moderate to severe acne vulgaris
NCT06090721Phase 3Completed
- Sponsor
- Dermata Therapeutics
- Start
- Dec 2023
- Primary completion
- Mar 2025
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acne vulgaris comparing DMT310 with Placebo (2 arms). Primary endpoints: Mean change from baseline in inflammatory lesion counts at 12 weeks, Mean change from baseline in non-inflammatory lesion counts at 12 weeks and 1 more. Started Dec 2023; status: completed.
02
Drugs
DMT310
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT06090721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06090721.